România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd - cipru - sunitinibum - caps. - 37,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd - cipru - sunitinibum - caps. - 50mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinom, pulmonar non-celulă mică - alte medicamente antineoplazice, inhibitori de proteinkinază - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sc balkan pharmaceuticals srl - mitoxantronum - concentrat pentru soluţie perfuzabilă - 2 mg/ml